Skip to main content
Caplight Logo









NephroDI Therapeutics

NephroDI Therapeutics

Private
Philadelphia, PennsylvaniaHealthcare & Life Scienceshttps://nephrodi.com/

Last Round

Series A

Jun 20, 2024

Total Funding Raised

$7.85M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

NephroDI Therapeutics is a biotechnology company developing novel kidney-targeted AMPK activators for the treatment of congenital nephrogenic diabetes insipidus.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biotechnologydrug discoverynephrogenic diabetes insipidusNDIorphan diseaserare diseasesmall moleculeAMPK activatorclinical trialsbiopharmakidney therapeuticspediatric medicineclinical-stage biotechdrug developmentpharmaceutical partnership

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

NephroDI Therapeutics Comparables

Compare NephroDI Therapeutics with similar companies based on industry and business-model similarity.

NephroDI Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
ePurines, Inc.
68%
Renibus Therapeutics
65%
Travere Therapeutics Inc
61%

NephroDI Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AJun 20, 2024
GrantSep 1, 2022
SeedFeb 23, 2021
GrantSep 15, 2020

Key People

Founding team and executive leadership

Rachael A Hagan

President and CEO

Executive Team

NephroDI Therapeutics Investors

Notable investors and investment history

NephroDI Therapeutics investors
InvestorRounds
XontogenySeed
National Institute of Diabetes and Digestive and Kidney DiseasesGrant
Sound BioventuresSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 21, 2026

    Monthly visitors increased 73% MoM.

  • Apr 17, 2026

    Monthly visitors increased 175% MoM, reaching 1.4K.

NephroDI Therapeutics Filings

Explore SEC and related filing metadata, where available.

NephroDI Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about NephroDI Therapeutics's valuation, stock price, and market status.

Is NephroDI Therapeutics a public or private company?

NephroDI Therapeutics is a private company.

What is the current stock price of NephroDI Therapeutics?

NephroDI Therapeutics is a private company with no public stock price. No recent secondary market data is available.

How much is NephroDI Therapeutics worth (valuation)?

Valuation information for NephroDI Therapeutics is not publicly available.

Can I buy NephroDI Therapeutics stock?

NephroDI Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was NephroDI Therapeutics's last funding round?

NephroDI Therapeutics's most recent funding round was Series A on June 20, 2024.

Who are the main investors in NephroDI Therapeutics?

Key investors in NephroDI Therapeutics include Xontogeny, Sound Bioventures.

Will NephroDI Therapeutics IPO soon?

No public IPO plans have been announced for NephroDI Therapeutics.

How can I track NephroDI Therapeutics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor NephroDI Therapeutics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersPhiladelphia, Pennsylvania
Employee Range5
Year Founded2017
Last FundingJun 20, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?